ILT4 facilitates angiogenesis in non-small cell lung cancer

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Anti-VEGF-A therapy is standard for non-small cell lung cancer (NSCLC) but has limited efficacy (<50% response) and frequent resistance.
• Resistance often stems from bypass signaling pathways reactivating angiogenesis and tumor growth.
• Novel proangiogenic mechanisms and therapeutic targets are needed to enhance anti-VEGF-A treatment outcomes.

Purpose of the Study:

• To investigate the role of immunoglobulin-like transcript 4 (ILT4) in non-small cell lung cancer (NSCLC) angiogenesis.
• To elucidate the underlying molecular mechanisms of ILT4-mediated tumor progression and angiogenesis in NSCLC.
• To evaluate ILT4 as a potential therapeutic target for improving antiangiogenic therapy in NSCLC.

Main Methods:

• Correlative analysis of ILT4 expression with microvessel density, disease stage, and survival in NSCLC patients.
• In vitro and in vivo studies assessing the impact of tumor cell-derived ILT4 on angiogenesis, tumor progression, and metastasis.
• Mechanistic studies involving angiopoietin-like protein 2 (ANGPTL2) and the ERK1/2 signaling pathway.

Main Results:

• Enriched ILT4 in NSCLC tissues correlated with increased microvessel density, advanced disease, and poorer survival.
• Tumor cell-derived ILT4 promoted angiogenesis in vitro and in vivo, alongside tumor progression and metastasis.
• ILT4, upregulated by ANGPTL2, activated ERK1/2 signaling, leading to increased VEGF-A and MMP-9 secretion.

Conclusions:

• Tumor cell-derived ILT4 drives NSCLC angiogenesis and progression through the ANGPTL2/ILT4/ERK1/2 axis.
• ILT4 represents a novel mechanism contributing to tumor angiogenesis and a potential therapeutic target in NSCLC.
• Targeting ILT4 may offer a strategy to overcome resistance and improve the efficacy of antiangiogenic therapies for NSCLC.